Cargando…

Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771

Detalles Bibliográficos
Autores principales:	Gray, Michael, Gong, Jian, Nguyen, Van, Osada, Takuya, Hartman, Zachary, Hutchins, Jeff, Freimark, Bruce, Lyerly, Kim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649312/ http://dx.doi.org/10.1186/2051-1426-3-S2-P357

Ejemplares similares

Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers
por: Gray, Michael J., et al.
Publicado: (2016)

Targeting of phosphatidylserine by monoclonal antibodies reverses an immunosuppressive checkpoint inducing innate and specific anti-tumor responses
por: Gong, Jian, et al.
Publicado: (2013)

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
por: Gong, Jian, et al.
Publicado: (2014)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers
por: Kaneko, Kensuke, et al.
Publicado: (2022)

Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
por: Huang, Xianming, et al.
Publicado: (2015)

Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma
por: Huang, Xianming, et al.
Publicado: (2014)

E0771 and 4T1 murine breast cancer cells and interleukin 6 alter gene expression patterns but do not induce browning in cultured white adipocytes
por: Pearce, Janina V., et al.
Publicado: (2019)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
por: Choi, Jin Wook, et al.
Publicado: (2020)

Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment
por: Yopp, Adam, et al.
Publicado: (2014)

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2020)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1
por: NISHIBORI, Shoma, et al.
Publicado: (2023)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Diets Differently Regulate Tumorigenesis in Young E0771 Syngeneic Breast Cancer Mouse Model
por: Thangavel, Hariprasad, et al.
Publicado: (2023)

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
por: Hack, Stephen P., et al.
Publicado: (2020)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
por: Belzile, Olivier, et al.
Publicado: (2018)

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer
por: Birge, R B, et al.
Publicado: (2016)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies
por: Al-Showbaki, Laith, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
por: de Moraes, Francisco Cezar Aquino, et al.
Publicado: (2023)

Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
por: Martomo, Stella A., et al.
Publicado: (2022)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis
por: Li, Han, et al.
Publicado: (2021)

Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma
por: Minoli, Lucia, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers
por: Yu, Jinling, et al.
Publicado: (2020)

Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway
por: Molina, Megan S., et al.
Publicado: (2022)

Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model
por: Yamaguchi, Izumi, et al.
Publicado: (2019)

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells
por: Martins, Christina, et al.
Publicado: (2022)

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
por: Yang, Qianmei, et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i9nk0am1cvrkdbrbj9qed8t5ra